Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board
June 16 2021 - 7:04AM
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced the appointment of Ms. Uta
Kemmerich-Keil as director on its Supervisory Board effective
immediately. The appointment was approved during the Annual General
Meeting of Shareholders on June 15, 2021.
“We are pleased to welcome Uta to Affimed’s Supervisory Board,”
said Dr. Thomas Hecht, Chairman of the Supervisory Board. “Uta
brings unique and very deep and extensive executive experience in
the life sciences industry. With over 20 years of leadership roles
in driving higher business performance for global pharmaceutical
companies, Uta will play a critical role in guiding Affimed as we
expand and advance our pipeline of novel immuno-oncology therapies
and prepare for the next step in our growth.”
Ms. Kemmerich-Keil brings senior executive, finance and M&A
expertise to Affimed and over 20 years of executive experience in
the pharmaceutical and chemical industry. Most recently she led the
international personal healthcare business of P&G and has over
19 years of experience at Merck KGaA, where she served, inter alia,
as CEO of the global OTC- and global Allergy business, EVP Finance,
Investor Relations and M&A. Ms. Kemmerich-Keil is a board
member of several public and privately held companies like Schott
AG, Gothaer Versicherung AG and Röchling S.E. She is a Board Member
and member of the Audit Committee of Karo Pharma AB (listed OMX
Stockholm). She holds a M.Sc. (Economics) and a M.A. (Roman
Philology) from Freiburg University and a Licence from Nouvelle
Sorbonne, Paris.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the company’s
people, pipeline and partners, please visit: www.affimed.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. Forward-looking statements appear
in a number of places throughout this release and include
statements regarding our intentions, beliefs, projections, outlook,
analyses and current expectations concerning, among other things,
the potential of AFM13, AFM24, and our other product candidates,
the value of our ROCK® platform, our ongoing and planned
preclinical development and clinical trials, our collaborations and
development of our products in combination with other therapies,
the timing of and our ability to make regulatory filings and obtain
and maintain regulatory approvals for our product candidates, our
intellectual property position, our collaboration activities, our
ability to develop commercial functions, clinical trial data, our
results of operations, cash needs, financial condition, liquidity,
prospects, future transactions, growth and strategies, the industry
in which we operate, the trends that may affect the industry or us,
impacts of the COVID-19 pandemic, the benefits to Affimed of orphan
drug designation and the risks, uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the SEC. Given these risks, uncertainties, and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Investor Relations ContactAlexander
FudukidisDirector, Head of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024